SAN DIEGO, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) securities between August 15, 2022 and September 27, 2023.

2023年12月15日，圣地亚哥（环球通讯社）——罗宾斯律师事务所提醒投资者，一名股东代表2022年8月15日至2023年9月27日期间购买或以其他方式收购Brainstorm Cell Therapeutics Inc.（纳斯达克：BCLI）证券的个人和实体提起集体诉讼。

Brainstorm Cell is a biotechnology company that develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases. For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is this Case About: Brainstorm Cell Therapeutics Inc.

Brainstorm Cell是一家生物技术公司，开发并商业化用于治疗神经退行性疾病的自体细胞疗法。欲了解更多信息，请提交表格，发送电子邮件至Aaron Dumas，Jr.，或致电（800）350-6003。这个案例是关于什么的：Brainstorm Cell Therapeutics Inc。

(BCLI) Misled Investors About the Viability and Efficacy of its drug NurOwn According to the complaint, on August 15, 2022, the Company issued a press release announcing its submission of a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for NurOwn for the treatment of amyotrophic lateral sclerosis (“ALS”).

（BCLI）误导投资者关于其药物NurOwn的可行性和有效性根据投诉，2022年8月15日，该公司发布新闻稿，宣布向美国食品和药物管理局（“FDA”）提交生物制剂许可证申请（“BLA”），用于治疗肌萎缩侧索硬化症（“ALS”）。

On November 10, 2022, the Company announced it had received a refusal to file letter from the FDA for its BLA for NurOwn for the treatment of ALS. On this news, Brainstorm Cell's share price fell 42.21%. Then, on September 27, 2023, the Company announced the results of the FDA’s review of its BLA. Members of the Cellular, Tissue, and Gene Therapies Advisory Committee voted 17 to 1 that there was not substantial evidence to show NurOwn’s effectiveness.

2022年11月10日，该公司宣布，它收到了美国食品和药物管理局（FDA）拒绝提交其针对NurOwn治疗ALS的BLA的信函。根据这条消息，Brainstorm Cell的股价下跌了42.21%。然后，2023年9月27日，该公司宣布了FDA对其BLA的审查结果。细胞，组织和基因治疗咨询委员会的成员以17比1的投票结果表明，没有实质性证据表明NurOwn的有效性。

On this news, Brainstorm Cell’s share price fell $0.19 per share, or 48.72%, to close at $0.2 per share on September 28, 2023. The complaint alleges that during the class period, defendants failed to disclose that Brainstorm Cell downplayed the severity of the FDA’s refusal to file letter and continued to conceal the risks associated with the submission of the BLA.

根据这条消息，Brainstorm Cell的股价在2023年9月28日下跌0.19美元，跌幅为48.72%，收于每股0.2美元。原告指控，在上课期间，被告未能透露Brainstorm Cell淡化了FDA拒绝提交信函的严重程度，并继续隐瞒与提交BLA相关的风险。

What Now: Si.

现在怎么办：是的。